Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73586839" target="_blank" >RIV/61989592:15110/17:73586839 - isvavai.cz</a>
Result on the web
<a href="https://data.epo.org/publication-server/pdf-document?pn=2924125&ki=B1&cc=EP" target="_blank" >https://data.epo.org/publication-server/pdf-document?pn=2924125&ki=B1&cc=EP</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimens for overcoming resistance
Original language description
The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells - the level of expression of at least one bromodomain containing gene, and/or - the level of expression of at least one bromodomain containing protein and/or - the mutations involving the non-synonymous change in amino acid sequence of at least one bromodomain containing gene and/or - the half maximal inhibitory concentration (IC 50 ) of a DNA methylation inhibitor and/or a histone demethylase inhibitor, wherein the increase in the half maximal inhibitory concentration of the DNA methylation inhibitor and/or the histone demethylase inhibitor signifies cross-resistance, and/or - the half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor, wherein the decrease in the half maximal inhibitory concentration of the selective BET bromodomain inhibitor signifies sensitivity. The invention further provides a combination therapy of cancers using bromodomain inhibitors in combination with DNA methylation inhibitors.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/TE02000058" target="_blank" >TE02000058: Center of competence for molecular diagnostics and personalized medicine</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP 2924125
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Jun 14, 2017
Owner name
Univerzita Palackého v Olomouci
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence